In the cohort of Sklar et al. [10], there was no increased risk of tumor recurrence in the event of treatment with GH (RR 0.98, CI 0.35–2.75, p = 0.96) in the 68 patients who had an astrocytoma. This evidence concerns the gene GH1 and astrocytoma (excluding glioblastoma).